Intraperitoneal taxanes.
The taxanes appear to be promising agents for intraperitoneal use. Paclitaxel is currently undergoing Phase III investigation for the treatment of ovarian cancer. Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy.